Retrospective Analyses of TrakStar Database

Neuronetics156,000 enrolled

Overview

In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

Study Type

OBSERVATIONAL

Enrollment

156,000

Conditions

Depression Obsessive-Compulsive Disorder Anxiety Depression

Interventions

NeuroStar Advanced TMS Therapy SystemDEVICE

non-invasive brain stimulation device

Eligibility

Sex: ALLMin age: 5 YearsMax age: 120 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date of November 01, 2008 or later. Exclusion Criteria: • Incomplete information on treatment parameters

Locations (1)

Neuronetics

Malvern, Pennsylvania, United States

RECRUITING

Outcomes

Primary Outcomes

Change in clinical assessment score from baseline to post-treatment

real-world efficacy of NeuroStar TMS in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9

Time frame: 8 weeks

Secondary Outcomes

Age at baseline and its correlation to change in score post treatment

Determine the patient characteristics like age that are associated with clinical outcomes- PHQ-9 following NeuroStar TMS

Time frame: 8 weeks

Central Contacts

Neha Goyal

CONTACT

763-528-1599 neha.goyal@neurostar.com

Eleanor Cole, PhD

CONTACT

415-724-7960 Eleanor.cole@neurostar.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.